[Assessment of job stress after implementation of prevention measures in a pension fund]. / Evaluation du stress au travail après mesures de prévention dans une caisse de retraite.

AIM: Work stress and its impact on health have been widely studied. However, very few studies have examined the effect of implementing measures designed to reduce work stress, a risk factor for psychological health problems. The purpose of this study was to fill this gap. METHODS: Two surveys were conducted in October 2009 and October 2011. 150 employees participated in the first trial, while 108 took part in the second trial. Among them, 74 employees participated in both surveys and were matched. Participation in the two surveys was anonymous and the participants were asked to complete three questionnaires. RESULTS: The intervention was not effective in reducing perceived poor health, accidents, hospitalizations, sick leaves, medication use, musculoskeletal disorders, psychosocial distress and job stress. However, there wasa significant decrease in iso-strain and an increase in social support. Iso-strain decreased, especially among women (p < 0.002) and employees (p < 0.001). The increased support provided by supervisors and colleagues benefited women and employees, while improved emotional support from supervisors and colleagues mainly benefited employees. These trends were associated with psychological and musculoskeletal disorders. CONCLUSIONS: The significant decrease of iso-strain through improved social support suggests that efforts to prevent work-related stress need to be pursued.

[Prostate Specific Antigen (PSA), yet how much damage?]. / Prostate Specific Antigen (PSA), encore combien de dégâts ?

Screening for prostate cancer has been widely promoted since the early 1990s despite the lack of evidence of its efficacy. The US Preventive Services Task Force recommended against PSA screening because there is sufficient evidence that the harms of screening outweigh its benefits. Yet more than half of French doctors are in favor of screening and the use of PSA assays continue to grow, by 4.6% between 2009 and 2010. The sale of a rapid immunological test for PSA, intended for home use, can only aggravate a situation already out of control. The role of the French authorities in the present situation cannot be ignored.